{"id":"NCT03642210","sponsor":"Medicines360","briefTitle":"Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding","officialTitle":"A Phase 3, Multicenter, Open-Label Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-17","primaryCompletion":"2021-10-12","completion":"2021-10-12","firstPosted":"2018-08-22","resultsPosted":"2024-05-14","lastUpdate":"2024-05-14"},"enrollment":105,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Menorrhagia"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Levonorgestrel 52 mg intrauterine system","otherNames":[]}],"arms":[{"label":"Levonorgestrel 52 mg intrauterine system","type":"EXPERIMENTAL"}],"summary":"To assess the efficacy of a levonorgestrel 52 mg intrauterine system as a treatment for heavy menstrual bleeding.","primaryOutcome":{"measure":"Number of Participants With Successful Treatment of Heavy Menstrual Bleeding","timeFrame":"6 months","effectByArm":[{"arm":"Levonorgestrel 52 mg Intrauterine System","deltaMin":81,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":14,"exclusionCount":25},"locations":{"siteCount":29,"countries":["United States"]},"refs":{"pmids":["37023455"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":105},"commonTop":["Bacterial vaginosis","Device expulsion","Pelvic pain","Nausea","Post procedural haemorrhage"]}}